(Q43947310)

28 November 2017

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia (English)

1 reference

Chronic phase chronic myelogenous leukemia

28 November 2017

0 references

16

Hagop M Kantarjian

1 reference

28 November 2017

6

Stefan Faderl

1 reference

28 November 2017

3

Jorge Cortes

1 reference

28 November 2017

1

Susan O'Brien

1 reference

28 November 2017

Guillermo Garcia-Manero

series ordinal

8

object named as

Guillermo Garcia-Manero

1 reference

28 November 2017

13

Michael Andreeff

1 reference

28 November 2017

15

Michael Keating

1 reference

28 November 2017

5

Francis J Giles

1 reference

28 November 2017

4

Jianqin Shan

1 reference

28 November 2017

2

Moshe Talpaz

1 reference

28 November 2017

9

Susie Mallard

1 reference

28 November 2017

14

Anthony Murgo

1 reference

28 November 2017

12

Steve Kornblau

1 reference

28 November 2017

Deborah Thomas

7

1 reference

28 November 2017

Mary Beth

series ordinal

10

1 reference

28 November 2017

Charles Koller

series ordinal

11

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

28 November 2017

1 reference

28 November 2017

94

1 reference

28 November 2017

2024-2032

1 reference

28 November 2017

7

1 reference

Chronic myelogenous leukemia: biology and therapy

28 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10436

21 January 2018

Identifiers

DOI

10.1002/CNCR.10436

1 reference

28 November 2017

1 reference